Company intelligence / Profile preview

NeoVista

Fremont, California, United Statesneovistagroup.com ↗

Ownership: Private
Development stage: Other

Overview

NeoVista developed an ophthalmic device called Epi-Rad90 for treating wet age-related macular degeneration using targeted radiation therapy. The company raised significant venture capital and advanced to late-stage clinical trials but has not reported new results or commercialization in over a decade[2][6].

Therapeutic areas: Ophthalmology
Modalities: Device
Industry: Therapeutic Medical Devices

Beyond the preview

Go deeper on NeoVista.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NeoVista.

Explore the full profile